FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890155867> ?p ?o ?g. }

• W2890155867 endingPage "106" @default.
• W2890155867 startingPage "99" @default.
• W2890155867 abstract "IntroductionHere we report efficacy and safety data of an Asian subset of the phase III FLAURA trial (NCT02296125), which compares osimertinib with standard of care (SoC) EGFR tyrosine kinase inhibitors (TKIs) in patients with previously untreated advanced NSCLC with tumors harboring exon 19 deletion (Ex19del)/L858R EGFR TKI–sensitizing mutations.MethodsEligible Asian patients (enrolled at Asian sites) who were at least 18 years of age (≥20 years in Japan) and had untreated EGFR-mutated advanced NSCLC were randomized 1:1 to receive osimertinib (80 mg, orally once daily) or an SoC EGFR TKI (gefitinib, 250 mg, or erlotinib, 150 mg, orally once daily). The primary end point was investigator-assessed progression-free survival (PFS). The key secondary end points were overall survival, objective response rate, central nervous system efficacy, and safety.ResultsThe median PFS was 16.5 versus 11.0 months for the osimertinib and SoC EGFR TKI groups, respectively (hazard ratio = 0.54, 95% confidence interval: 0.41–0.72, p < 0.0001). The overall survival data were immature (24% maturity). The objective response rates were 80% for osimertinib and 75% for an SoC EGFR TKI. The median central nervous system PFS was not calculable for the osimertinib group and was 13.8 months for the SoC EGFR TKI group (hazard ratio = 0.55, 95% confidence interval: 0.25–1.17, p = 0.118). Fewer adverse events of grade 3 or higher (40% versus 48%) and fewer adverse events leading to treatment discontinuation (15% versus 21%) were reported with osimertinib versus with an SoC EGFR TKI, respectively.ConclusionIn this Asian population, first-line osimertinib demonstrated a clinically meaningful improvement in PFS over an SoC EGFR TKI, with a safety profile consistent with that for the overall FLAURA study population." @default.
• W2890155867 created "2018-09-27" @default.
• W2890155867 creator A5001297228 @default.
• W2890155867 creator A5005962138 @default.
• W2890155867 creator A5006820907 @default.
• W2890155867 creator A5028432965 @default.
• W2890155867 creator A5028631107 @default.
• W2890155867 creator A5042110139 @default.
• W2890155867 creator A5047714811 @default.
• W2890155867 creator A5053390754 @default.
• W2890155867 creator A5061033724 @default.
• W2890155867 creator A5061940066 @default.
• W2890155867 creator A5063817865 @default.
• W2890155867 creator A5064697305 @default.
• W2890155867 creator A5072724155 @default.
• W2890155867 creator A5072962250 @default.
• W2890155867 creator A5076948015 @default.
• W2890155867 creator A5086784581 @default.
• W2890155867 creator A5087211784 @default.
• W2890155867 creator A5088178599 @default.
• W2890155867 creator A5090846902 @default.
• W2890155867 date "2019-01-01" @default.
• W2890155867 modified "2023-10-16" @default.
• W2890155867 title "Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset" @default.
• W2890155867 cites W2088540000 @default.
• W2890155867 cites W2099180737 @default.
• W2890155867 cites W2103940769 @default.
• W2890155867 cites W2133149289 @default.
• W2890155867 cites W2160982674 @default.
• W2890155867 cites W2163351155 @default.
• W2890155867 cites W2166084034 @default.
• W2890155867 cites W2171139285 @default.
• W2890155867 cites W2530508394 @default.
• W2890155867 cites W2560717039 @default.
• W2890155867 cites W2610486351 @default.
• W2890155867 cites W2760639821 @default.
• W2890155867 cites W2770828094 @default.
• W2890155867 cites W2809455848 @default.
• W2890155867 cites W4242460399 @default.
• W2890155867 doi "https://doi.org/10.1016/j.jtho.2018.09.004" @default.
• W2890155867 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30240852" @default.
• W2890155867 hasPublicationYear "2019" @default.
• W2890155867 type Work @default.
• W2890155867 sameAs 2890155867 @default.
• W2890155867 citedByCount "70" @default.
• W2890155867 countsByYear W28901558672019 @default.
• W2890155867 countsByYear W28901558672020 @default.
• W2890155867 countsByYear W28901558672021 @default.
• W2890155867 countsByYear W28901558672022 @default.
• W2890155867 countsByYear W28901558672023 @default.
• W2890155867 crossrefType "journal-article" @default.
• W2890155867 hasAuthorship W2890155867A5001297228 @default.
• W2890155867 hasAuthorship W2890155867A5005962138 @default.
• W2890155867 hasAuthorship W2890155867A5006820907 @default.
• W2890155867 hasAuthorship W2890155867A5028432965 @default.
• W2890155867 hasAuthorship W2890155867A5028631107 @default.
• W2890155867 hasAuthorship W2890155867A5042110139 @default.
• W2890155867 hasAuthorship W2890155867A5047714811 @default.
• W2890155867 hasAuthorship W2890155867A5053390754 @default.
• W2890155867 hasAuthorship W2890155867A5061033724 @default.
• W2890155867 hasAuthorship W2890155867A5061940066 @default.
• W2890155867 hasAuthorship W2890155867A5063817865 @default.
• W2890155867 hasAuthorship W2890155867A5064697305 @default.
• W2890155867 hasAuthorship W2890155867A5072724155 @default.
• W2890155867 hasAuthorship W2890155867A5072962250 @default.
• W2890155867 hasAuthorship W2890155867A5076948015 @default.
• W2890155867 hasAuthorship W2890155867A5086784581 @default.
• W2890155867 hasAuthorship W2890155867A5087211784 @default.
• W2890155867 hasAuthorship W2890155867A5088178599 @default.
• W2890155867 hasAuthorship W2890155867A5090846902 @default.
• W2890155867 hasBestOaLocation W28901558671 @default.
• W2890155867 hasConcept C121608353 @default.
• W2890155867 hasConcept C126322002 @default.
• W2890155867 hasConcept C143998085 @default.
• W2890155867 hasConcept C197934379 @default.
• W2890155867 hasConcept C203092338 @default.
• W2890155867 hasConcept C207103383 @default.
• W2890155867 hasConcept C2777626846 @default.
• W2890155867 hasConcept C2778087573 @default.
• W2890155867 hasConcept C2778715236 @default.
• W2890155867 hasConcept C2779438470 @default.
• W2890155867 hasConcept C2780580887 @default.
• W2890155867 hasConcept C2780739268 @default.
• W2890155867 hasConcept C3019894029 @default.
• W2890155867 hasConcept C44249647 @default.
• W2890155867 hasConcept C535046627 @default.
• W2890155867 hasConcept C71924100 @default.
• W2890155867 hasConceptScore W2890155867C121608353 @default.
• W2890155867 hasConceptScore W2890155867C126322002 @default.
• W2890155867 hasConceptScore W2890155867C143998085 @default.
• W2890155867 hasConceptScore W2890155867C197934379 @default.
• W2890155867 hasConceptScore W2890155867C203092338 @default.
• W2890155867 hasConceptScore W2890155867C207103383 @default.
• W2890155867 hasConceptScore W2890155867C2777626846 @default.
• W2890155867 hasConceptScore W2890155867C2778087573 @default.
• W2890155867 hasConceptScore W2890155867C2778715236 @default.
• W2890155867 hasConceptScore W2890155867C2779438470 @default.
• W2890155867 hasConceptScore W2890155867C2780580887 @default.

• next